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Background: Durable polymers in 1st generation DES have been linked to coronary inflammation and life-threatening adverse events. Polymer-free 
DES have risen as an alternative to minimize these untoward effects. We sought to assess the efficacy of the novel VESTAsync Eluting Stent (VES) 
combining a Cro-Co platform with a nanothin-microporous hydroxyapatite surface coating impregnated with a polymer-free low-dose of Sirolimus 
(55μg).
Methods: The Vestasync II trial is a randomized (2:1), blinded, multicenter comparison of the VES to its platform, the Gen X stent, with microporous 
hydroxyapatite coating but without sirolimus. Pts were eligible if they had de novo lesions up to 14mm in native coronaries of 2.5-3.5mm. Primary 
endpoint was 9-month in-stent late loss - LL (QCA) and % of stent obstruction (IVUS) assessed by independent corelabs.
Results: Sixty pts (40 treated with VES) were enrolled, with mean age of 57 yrs and 23% of DM. RVD and lesion length were 2.7mm and 14.2 mm. 
At 9 months VES showed superior reduction in LL (0.39mm vs. 0.74mm, p<0.001) and % of stent obstruction (9.3±6.6% vs. 17.6±9.4%, p=0.0016). 
There was one case of late-acquired incomplete stent apposition (with the VES). The chart shows the % of NIH distribution for both stents. Up to one 
year there were 2 deaths and 2 TLR, evenly distributed in the cohorts.
Conclusion: In this preliminary report, the polymer-free VES showed superior efficacy over the GEN X, with similar safety profile. Longer term results 
in more complex cohorts are warranted. 
